CoChat

Ablation of amyloid precursor protein increases insulin-degrading enzyme levels and activity in brain and peripheral tissues

Open access
Kulas, Joshua A., Franklin, Whitney F., Smith, Nicholas A., Manocha, Gunjan D., Puig, Kendra L., Nagamoto-Combs, Kumi, Hendrix, Rachel D., Taglialatela, Giulio, Barger, Steven W., Combs, Colin K. · 2019 · American Journal of Physiology-Endocrinology and Metabolism
Cited by 41

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Abstract

The amyloid precursor protein (APP) is a type I transmembrane glycoprotein widely studied for its role as the source of β-amyloid peptide, accumulation of which is causal in at least some cases of Alzheimer’s disease (AD). APP is expressed ubiquitously and is involved in diverse biological processes. Growing bodies of evidence indicate connections between AD and somatic metabolic disorders related to type 2 diabetes, and App−/−mice show alterations in glycemic regulation. We find that App−/−mice have higher levels of insulin-degrading enzyme (IDE) mRNA, protein, and activity compared with wild-type controls. This regulation of IDE by APP was widespread across numerous tissues, including liver, skeletal muscle, and brain as well as cell types within neural tissue, including neurons, astrocytes, and microglia. RNA interference-mediated knockdown of APP in the SIM-A9 microglia cell line elevated IDE levels. Fasting levels of blood insulin were lower in App−/−than App+/+mice, but the former showed a larger increase in response to glucose. These low basal levels may enhance peripheral insulin sensitivity, as App−/−mice failed to develop impairment of glucose tolerance on a high-fat, high-sucrose (“Western”) diet. Insulin levels and insulin signaling were also lower in the App−/−brain; synaptosomes prepared from App−/−hippocampus showed diminished insulin receptor phosphorylation compared with App+/+mice when stimulated ex vivo. These findings represent a new molecular link connecting APP to metabolic homeostasis and demonstrate a novel role for APP as an upstream regulator of IDE in vivo.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1152/ajpendo.00279.2018

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Cited by

See all 41

Metadata

Authors
Kulas, J. A., Franklin, W. F., Smith, N. A., Manocha, G. D., Puig, K. L., Nagamoto-Combs, K., Hendrix, R. D., Taglialatela, G., Barger, S. W., & Combs, C. K.
Venue
American Journal of Physiology-Endocrinology and Metabolism
Published
2019-01-01
Volume
316
Issue
1
Pages
E106-E120
ISSN
  • 0193-1849 (ISSN-L)
  • 1522-1555
OpenAlex
W2901975083
Cited by
41
References
13
FWCI
1.93
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Ablation of amyloid precursor protein increases insulin-degrading enzyme levels and activity in brain and peripheral tissues. https://app.cochat.ai/papers/10.1152/ajpendo.00279.2018
The paper
Kulas, J. A., Franklin, W. F., Smith, N. A., Manocha, G. D., Puig, K. L., Nagamoto-Combs, K., Hendrix, R. D., Taglialatela, G., Barger, S. W., & Combs, C. K. (2019). Ablation of amyloid precursor protein increases insulin-degrading enzyme levels and activity in brain and peripheral tissues. American Journal of Physiology-Endocrinology and Metabolism. https://doi.org/10.1152/ajpendo.00279.2018

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.